Optipres Eye Drop contains Netarsudil 0.2 mg, a potent Rho kinase inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Netarsudil works by increasing the outflow of aqueous humor through the trabecular meshwork, thereby effectively lowering IOP and helping to prevent optic nerve damage and subsequent vision loss. Optipres Eye Drop is administered topically, typically as one drop in the affected eye(s) once daily in the evening, ensuring optimal therapeutic efficacy. It is essential to adhere strictly to the prescribed dosage and avoid contamination of the dropper tip to prevent ocular infections. Common adverse effects may include conjunctival hyperemia, eye discomfort, and mild irritation; however, these are generally transient and well-tolerated. Patients should inform their healthcare provider of any history of eye surgery, infections, or hypersensitivity to any component of the formulation. Regular monitoring of intraocular pressure is recommended to assess treatment response. Optipres Eye Drop should be used with caution in pregnant or breastfeeding women and only if the potential benefit justifies the potential risk. This medication is a valuable option in the management of glaucoma and ocular hypertension to preserve visual function.